RAPIVAB (Seqirus Pty Ltd)
Product name
RAPIVAB
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
peramivir
Registration type
NCE/NBE
Indication
RAPIVAB (concentrate for intravenous infusion) is indicated for the treatment of acute influenza infection in adults and children 2 years and older who have been symptomatic for no more than two days.